Academic degree: Dr. of Sci. (Med)

Academic title: Academician RAS, Professor

Place of work:

1.    Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences (Polio Institute)

2.    I.M. Sechenov First Moscow State Medical University (Sechenov University)

Position:

1.    General Director
2.    Head of the Department of Organization and Production Technology of Immunobiological Preparations

Research interests: allergology, immunology

Address: Moscow, Russia

E-mail: Aydar.ishmuhkametov@remedium.ru

ORCID iD: 0000-0001-6130-4145
Scopus Author ID: 57195034442
Researcher ID: L-4482-2018
PubMed

Main scientific achievements:

1.    Methods of determination of immune status disorders and individual sensitivity to plasmapheresis in patients with rheumatoid arthritis have been developed and introduced into medical practice.
2.    A unique methodology of production of information-analytical systems reflecting the current state of the pharmaceutical industry is created.
3.    The basic principles of creating a unified information environment in the field of drug circulation are formulated and justified.
4.    The Unified Information and Search System of the Public Oversight Authorities of the Ministry of Health of the Russian Federation has been developed.
5.    The State Register of Medicinal Products has been compiled and published.
6.    The concept of development of the Federal State Unitary Enterprise "M.P. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, RAS" was suggested, which combined scientific, technological and production aspects of the development of innovative drugs. This made it possible to develop a number of antiviral vaccines in the shortest possible time, among them:

• BiVac polio on the basis of live, attenuated strains of polioviruses of type 1 (LSc2ab) and 3 (Leon12a1b), preclinical and clinical studies of the drug were conducted, registration certificate was obtained;
• MonoBac polio type 2, preclinical and clinical studies of the preparation were conducted;
• EverVac against tick-borne encephalitis using transplanted mammalian cell cultures. The drug underwent preclinical studies;
• new inactivated trivalent polio vaccine based on Sabin strains (S-IPV), the drug is undergoing preclinical studies;
• The development of experimental industrial technology of vaccine production for prevention of hemorrhagic fever with renal syndrome has been completed.